“Dupilumab in Moderate-to-Severe Atopic Dermatitis: Pooled Efficacy Results from Two Identically Designed Randomized Phase 3 Trials (SOLO 1 & 2)”. 2017. SKIN The Journal of Cutaneous Medicine 1 (3.1): s38. https://doi.org/10.25251/skin.1.supp.37.